Clinical trial NCT01371175: A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers
Official title: A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HIV Infections
Keywords: HIV
Lead sponsor: International AIDS Vaccine Initiative
Sponsor class: NETWORK
Collaborators: name: Medical Research Council-Oxford
name: University of Nairobi
First posted: 2011-06-10
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the safety and tolerability of plasmid DNA and recombinant MVA (Modified Vaccinia Virus Ankara) in a prime-boost regimen.

Approximately 111 volunteers (90 vaccine recipients/21 placebo recipients) will be enrolled at two sites. Approximately 56 volunteers will be enrolled at each site. An over-enrolment of up to 10% (approximately 10 additional volunteers) will be permitted in the study.


Eligibility criteria: Inclusion Criteria

1. Healthy males and females;
2. Age at least 18 years on the day of screening and no greater than 60 years on the day of enrolment;
3. Available for follow up for the planned duration of the study (screening plus 18 months);
4. Able to give written informed consent;
5. Does not engage in risk behaviour as defined by the protocol, willing to undergo HIV testing and receive results;
6. If sexually active female, using an effective method of contraception (combined oral contraceptive pill; injectable contraceptive; IUCD; condoms; anatomical sterility in self or partner) from screening until at least 4 months after last vaccination and willing to undergo urine pregnancy tests at screening and prior to each vaccination and 4 months after the last vaccination;
7. If sexually active male, willing to use an effective method of contraception (such as condoms) from screening until 4 months after the last vaccination.

Exclusion Criteria:

1. Clinically relevant abnormality on history or examination including history of immunodeficiency or use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the designated trial physician in last 6 months;
2. Presence of any chronic condition;
3. Any of the following abnormal laboratory parameters that are moderate, severe, or very severe: haematology (haemoglobin, absolute neutrophil count absolute lymphocyte count , absolute CD4 count, platelets); urinalysis, biochemistries (total bilirubin, creatinine, AST, ALT). Volunteers with mild laboratory abnormalities which are judged by the principal investigator or designee to be not clinically significant may be enrolled.
4. If female, pregnant or planning a pregnancy within 4 months after last vaccination or lactating;
5. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment;
6. Receipt of blood transfusion or blood products 6 months prior to enrolment;
7. Participation in another clinical trial of an investigational product currently or within last 12 weeks or expected participation during this study;
8. History of severe local or general reaction to vaccination or history of allergic reactions;
9. History of grand-mal epilepsy, or currently taking anti-epileptics;
10. Confirmed HIV-1 or HIV-2 seropositive;
11. Positive for hepatitis B (surface antigen) or confirmed diagnosis of active syphilis at the time of enrolment (RPR positive and TPHA positive or equivalent), positive for hepatitis C antibodies;
12. Unlikely to comply with protocol. Prior receipt of smallpox vaccination should be documented, but will not be an exclusion criterion.

Primary outcomes:
measure: Safety (local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse events)
timeFrame: 18 months
Secondary outcomes:
measure: Immunogenicity: Proportion of volunteers with HIV-1 specific T-cell responses by ELISPOT assay.
timeFrame: Day 0, Month 1, Month 2, Month 5, Month 6, Month 8, Month 9, Month 12, Month 18
Other outcomes:
Locations:
city: Nairobi
country: Kenya
facility: KAVI (Kenya AIDS Vaccine Initiative)
city: London
country: United Kingdom
facility: Guys and St. Thomas' Hospital
Study officials:
affiliation: Guys and St. Thomas' Hospital
name: Barry S. Peters, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: KAVI (Kenya AIDS Vaccine Initiative)
name: Walter Jaoko
role: PRINCIPAL_INVESTIGATOR
References: